DDE MRI Solutions is aiming to convert existing MRI systems into safe and accurate systems for the detection and diagnosis of breast and prostate cancer. The DDE solution, which does not use any contrast injection, is clinically proven with hundreds of exams performed showing equivalence or higher accuracy in comparison with contrast enhanced MRI. DDE is a platform technology currently also being tested for prostate cancer diagnosis. The DDE solution consists of two parts: a unique configuration of MRI protocol, and a proprietary image analysis software. The patented DDE solution operates with existing MRI systems, with no hardware modification required. In addition, the method is completely safe and non-invasive:It does not require an injection of MRI contrast material unlike the existing breast MRI and hence: does not lead to allergic reactions;* Safe to be used in patients with renal failure;* Safe to be used in pregnant or breast feeding patient; * Eliminates the risk of nephrogenic systemic fibrosis (NSF) and deposition of the contrast material (Gadolinium compounds) in the brain. In addition, DDE can save on contrast material costs and on its administration (done by a physician), and its turnaround time is shortened by 40-50%.